My Cart [ 0 ]
Home > Cell Biology > Stable Cell Lines > Avastin Biosimilar Stable Cell Line

Avastin Biosimilar Stable Cell Line

Bevacizumab, Anti-VEGF-A Humanized Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C001 Avastin Biosimilar Stable Cell Line 1 package Request

Bevacizumab (trade name Avastin, Genentech/Roche), the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

C001: Avastin Biosimilar Stable Cell Line (CHO)

The yield of Avastin biosimilar from the CHO stable cell line was above 1.7 g/L in a 750 liter manufacturing.

The Avastin stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.

Syd Labs also provides the following VEGF-A antibody biosimilar cell line:
Lucentis Biosimilar Cell Line (Fab produced in E. coli)

Related Links

See our Privacy Policy